All drugs were administered i.p. except L-741,626 which was administered s.c. Rats were tested in 3 cohorts of n = 16 each. Cohort 1 (n = 16) received bromocriptine (D2/3 dopamine receptor agonist; Tocris Bioscience), which was prepared in 50:50 DMSO and 0.9% saline. Cohort 2 (n=16) received PD128907 (selective D3 receptor agonist; Tocris Bioscience), which was prepared in 0.9% saline. Cohort 3 (n=16) received L-741,626 (selective D2 receptor antagonist), SB-77011-A (selective D3 receptor antagonist) and Sumanirole (selective D2 receptor agonist). L-741,626 (Sigma-Aldrich) was prepared in 51.67% DMSO and 48.33% saline. SB-77011-A (Tocris Bioscience) was prepared in 50:50 DMSO and 0.9% saline. Sumanirole (Sigma-Aldrich) was prepared in 0.9% saline. The drug doses and timing of injections prior to testing were based on previous studies that used these drugs in comparable behavioral tasks (Fernando et al., 2011; Koffarnus et al., 2011 (link), Simon et al., 2011 (link); St Onge and Floresco 2009 (link))..